Learn about our signature initiatives:
-
Public Law No: 115-180, The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act of 2018
-
A coordinated community campaign that allows individuals and organizations to work together to highlight and educate decision makers and the general public about the crucial need for increased childhood cancer funding.
Click below to learn more about some of our legislative activity in Washington.
-
STAR Act Appropriations Update
Posted on 08/21/2018 -
The Alliance for Childhood Cancer Lauds Passage of Historic Childhood Cancer Legislation
Posted on 05/22/2018 -
Alliance Appropriations FY19
Posted on 03/09/2018 -
Action Days 2017 Legislative Requests
Posted on 06/01/2017 -
Alliance PDUFA Mark Up Commentary
Posted on 05/17/2017 -
Alliance PDUFA Commentary
Posted on 05/09/2017 -
Research to Accelerate Cures and Equity (RACE) for Children Act (S. 456/H.R. 1231) Endorsement Letter
Posted on 03/22/2017 -
Alliance ACA Letter
Posted on 02/27/2017 -
Translating Discovery into Cures for Children with Cancer
Posted on 09/08/2016Translating Discovery into Cures for Children with Cancer Childhood
Cancer Research Landscape Report - Executive Summary -
Advancing Drug Development for Childhood Cancer: Policy Principles to Optimize the Pediatric Drug Laws
Posted on 06/10/2016Report of the BPCA/PREA Working Group
-
FDA BPCA PREA remarks
Posted on 10/22/2015Alliance for Childhood Cancer - Remarks on Changes to the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA)
-
Fiscal Year Appropriations for NIH and NCI
Posted on 07/21/2015Appropriations for the National Institutes of Health and National Cancer Institute
-
21st Century Cures
Posted on 05/18/2015 -
Childhood Cancer Policy Roundtable, part III
Posted on 02/27/2015 -
The STAR Act
Posted on 02/09/2015H.R. 820/S. 292, The Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act of 2017
-
NCI Meeting Request
Posted on 08/29/2014 -
Alliance FDA Comments
Posted on 03/10/2014Alliance for Childhood Cancer Letter to FDA RE: Response to Request for Comments following Public Workshop on Complex Issues in Developing Drug and Biological Products for Rare Diseases
-
Alliance Budget Conferees Letter
Posted on 11/12/2013 -
Childhood Cancer Survivors Alliance Endorsement Letter
Posted on 05/14/2013
